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Figure 1. Perception of Likelihood of cure with HSCT (P < 0.0001)
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S193gender, disease type and type of transplant. The IgG levels in
the normal range and the IgG levels in the low range were
compared and analyzed based on type of transplant, disease,
age (at transplant), and gender.
Results: 76 charts were reviewed. 10 charts had no post-
transplant levels ever documented. 53 had normal IgG levels,
and 13 had low IgG levels post-transplant. Characteristics
common to the majority of patients with low IgG included
allogeneic transplantation and leukemia or lymphoma as a
diagnosis.
Conclusions: IVIG replacement is not indicated based on
levels of IgG in patients undergoing autologous stem cell
transplantation or who have an underlying diagnosis other
than leukemia or lymphoma.288
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Introduction: During hematopoietic stem cell trans-
plantation (HSCT), patients receive high dose chemotherapyTable 1
Longitudinal QOL and Mood by type of HSCT
Outcomes Type
HSCT
Week-1 Week-2 Week-3 P-Value
QOL, M Auto
Allo
105.8
101.1
95.4
97.6
93.7
96.3
P ¼ 0.0003
P[ 0.01
Fatigue, M Auto
Allo
34.4
39.0
27.0
34.9
27.3
29.7
P < 0.0001
P[ 0.01
HADS depression
> 7, N (%)
Auto
Allo
7 (23%)
3 (13%)
11 (37%)
6 (26%)
13 (43%)
6 (26%)
P ¼ 0.0003
P[ 0.05during a prolonged hospitalization and endure signiﬁcant
side effects in the hopes of curing their disease. While many
studies have focused on the long-term outcomes of patients
undergoing HSCT, the acute impact of hospitalization for
HSCT on patients’ quality of life (QOL), symptom burden, and
mood is unknown. Furthermore, data on patients’ perception
of their prognosis and likelihood of cure with HSCT are
lacking.
Methods: We conducted a prospective longitudinal study of
patients hospitalized at the Massachusetts General Hospital
for HSCT. At baseline and weeks 1, 2, and 3 of hospitalization,
we assessed QOL (Functional Assessment of Cancer Therapy-
Bone Marrow Transplantation [FACT-BMT]; higher scores
indicate better QOL), fatigue (FACT-Fatigue; higher scores
indicate less fatigue), and mood (Hospital Anxiety and
Depression Scale score> 7 on anxiety or depression subscale
considered clinically signiﬁcant). Using a 10-item question-
naire, we measured patients’ information preferences, and
perception of their prognosis.
Results: We enrolled 53 consecutive patients undergoing
autologous (n¼30), ormyeloablative allogeneic (n¼23) HSCT.
Patients’ QOL declined (FACT BMT mean scores week 1:107.5
àweek 2: 96.3 àweek 3: 94.8, p < 0.0001), and fatigue
increased (FACT Fatigue mean scores week1: 36.4 à week 2:
30.5 à week 3: 28.3, p < 0.0001) throughout hospitalization.
The proportion of patients with depression symptoms
increased from baseline to week 3 (18.9% to 35.8%; p¼0.002)
whereas the proportion of patients with anxiety symptoms
did not change signiﬁcantly from baseline (22.6%; p¼0.7).
These patterns remained consistent when data were strati-
ﬁed by the type of HSCT [Table 1]. Although 90.6% (48/53) of
patients stated that it is ‘extremely’ or ‘very’ important to
know about their prognosis, 76.0% (38/50) reported inaccu-
rate and overly optimistic perception of their prognosis
compared to their physicians (p < 0.0001) [Figure 1].
Conclusion: Patients with hematologic malignancies un-
dergoing HSCT report an overly optimistic perception of their
prognosis and experience signiﬁcant decline in QOL with
increasing symptom burden and rates of depression
throughout their hospitalization. Results suggest that in-
terventions to both improve the QOL and psychological
outcomes of patients hospitalized for HSCT and enhance
their prognostic awareness are clearly warranted.289
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